Suppr超能文献

根据临床总体印象量表确定的早期无反应预示着,使用第二代抗精神病药物进行自然治疗的精神分裂症谱系障碍青年患者的预后较差。

Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.

作者信息

Stentebjerg-Olesen Marie, Jeppesen Pia, Pagsberg Anne K, Fink-Jensen Anders, Kapoor Sandeep, Chekuri Raja, Carbon Maren, Al-Jadiri Aseel, Kishimoto Taishiro, Kane John M, Correll Christoph U

机构信息

1 Mental Health Centre for Child and Adolescent Psychiatry , Glostrup, Denmark .

出版信息

J Child Adolesc Psychopharmacol. 2013 Dec;23(10):665-75. doi: 10.1089/cap.2013.0007. Epub 2013 Nov 22.

Abstract

OBJECTIVE

The use of early response/nonresponse (ER/ENR) to antipsychotics as a predictor for ultimate response/nonresponse (UR/UNR) may help decrease inefficacious treatment continuation. However, data have been limited to adults, and ER/ENR has only been determined using time-consuming psychopathology rating scales. In the current study, we assessed if early improvement on the Clinical Global Impressions-Improvement (CGI-I) scale predicted UR/UNR in psychiatrically ill youth started on antipsychotic treatment.

METHODS

Seventy-nine youth aged 6-19 years, with schizophrenia spectrum disorders, treated naturalistically with aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone and evaluated monthly, were divided into ER/ENR groups at week 4, using at least "minimally improved" on the CGI-I scale. Prediction using week 4 ER/ENR status for UR (CGI-I=at least "much improved"), effectiveness and adverse effect outcomes at 8-12 weeks were assessed.

RESULTS

At 4 weeks, 45.6% of subjects were ER and 54.4% were ENR without differences regarding baseline demographic, illness, and treatment variables, except for higher age (p=0.034) and maximum risperidone dose (p=0.0043) in ENR. ER/ENR status at 4 weeks predicted UR/UNR at week 12 significantly (p<0.0001): Sensitivity=68.9%, specificity=85.3%, positive predictive value=86.1%, negative predictive value=67.4%. At weeks 4, 8, and 12, ER patients improved significantly more on the CGI-I, CGI-Severity, and Children's Global Assessment of Functioning scales, and more ER patients reached UR compared with ENR patients (83.3% vs. 34.9%, all p<0.0001). ENR patients had more extrapyramidal side effects (EPS) at weeks 4, 8, and 12 (p=0.0019-0.0079). UR was independently associated with ER (odds ratio [OR]=18.09; 95% confidence interval [CI]=4.71-91.68, p<0.0001) and psychosis not otherwise specified (NOS) (OR=4.82 [CI: 1.31-21.41], p=0.017) (r(2)=0.273, p<0.0001).

CONCLUSIONS

Older age and EPS were associated with ENR; ENR and schizophrenia were associated with UNR in naturalistically treated youth with schizophrenia spectrum disorders. Early CGI-I-based treatment decisions require further consideration and study.

摘要

目的

将抗精神病药物的早期反应/无反应(ER/ENR)用作最终反应/无反应(UR/UNR)的预测指标,可能有助于减少无效治疗的持续时间。然而,相关数据仅限于成年人,且ER/ENR仅通过耗时的精神病理学评定量表来确定。在本研究中,我们评估了在开始接受抗精神病药物治疗的精神病性障碍青少年中,临床总体印象改善量表(CGI-I)上的早期改善是否能预测UR/UNR。

方法

79名年龄在6至19岁、患有精神分裂症谱系障碍的青少年,接受阿立哌唑、奥氮平、喹硫平、利培酮或齐拉西酮的自然主义治疗,每月进行评估。在第4周时,根据CGI-I量表上至少“稍有改善”,将他们分为ER/ENR组。评估使用第4周的ER/ENR状态预测UR(CGI-I=至少“明显改善”)、8至12周时的疗效和不良反应结果。

结果

在第4周时,45.6%的受试者为ER,54.4%为ENR,除了ENR组年龄较大(p=0.034)和利培酮最大剂量较高(p=0.0043)外,在基线人口统计学、疾病和治疗变量方面无差异。第4周时的ER/ENR状态显著预测了第12周时的UR/UNR(p<0.0001):敏感性=68.9%,特异性=85.3%,阳性预测值=86.1%,阴性预测值=67.4%。在第4、8和12周时,ER组患者在CGI-I、CGI-严重程度和儿童总体功能评估量表上的改善明显更多,与ENR组患者相比,达到UR的ER组患者更多(83.3%对34.9%,所有p<0.0001)。ENR组患者在第4、8和12周时锥体外系副作用(EPS)更多(p=0.0019至0.0079)。UR与ER独立相关(优势比[OR]=18.09;95%置信区间[CI]=4.71至91.68,p<0.0001)以及未另行说明的精神病(NOS)(OR=4.82[CI:1.31至21.41],p=0.017)(r(2)=0.273,p<0.0001)。

结论

年龄较大和EPS与ENR相关;在接受自然主义治疗的精神分裂症谱系障碍青少年中,ENR和精神分裂症与UNR相关。基于早期CGI-I的治疗决策需要进一步考虑和研究。

相似文献

4
Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
J Am Acad Child Adolesc Psychiatry. 2013 Jul;52(7):689-698.e3. doi: 10.1016/j.jaac.2013.04.018. Epub 2013 Jun 5.
6
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.
J Child Adolesc Psychopharmacol. 2021 Feb;31(1):46-52. doi: 10.1089/cap.2020.0030. Epub 2020 Jul 1.
7
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9.
8
The heterogeneity of antipsychotic response in the treatment of schizophrenia.
Psychol Med. 2011 Jun;41(6):1291-300. doi: 10.1017/S0033291710001893. Epub 2010 Oct 7.
10
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
J Am Acad Child Adolesc Psychiatry. 2015 Sep;54(9):718-727.e3. doi: 10.1016/j.jaac.2015.06.015. Epub 2015 Jul 7.

引用本文的文献

1
Progressive Changes in Glutamate Concentration in Early Stages of Schizophrenia: A Longitudinal 7-Tesla MRS Study.
Schizophr Bull Open. 2021 Feb 2;2(1):sgaa072. doi: 10.1093/schizbullopen/sgaa072. eCollection 2021 Jan.
3
Therapeutic abstention in the treatment of depression in first-episode psychosis.
J Psychiatry Neurosci. 2020 Nov;44(6):441-442. doi: 10.1503/jpn.200059.
5
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.
Ther Adv Psychopharmacol. 2018 Oct 8;8(11):303-318. doi: 10.1177/2045125318781475. eCollection 2018 Nov.
7
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
J Am Acad Child Adolesc Psychiatry. 2015 Sep;54(9):718-727.e3. doi: 10.1016/j.jaac.2015.06.015. Epub 2015 Jul 7.
9
Clinical predictors of therapeutic response to antipsychotics in schizophrenia.
Dialogues Clin Neurosci. 2014 Dec;16(4):505-24. doi: 10.31887/DCNS.2014.16.4/mcarbon.
10
Prediction of treatment outcomes in psychiatry--where do we stand ?
Dialogues Clin Neurosci. 2014 Dec;16(4):455-64. doi: 10.31887/DCNS.2014.16.4/fmcmahon.

本文引用的文献

1
Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
J Am Acad Child Adolesc Psychiatry. 2013 Jul;52(7):689-698.e3. doi: 10.1016/j.jaac.2013.04.018. Epub 2013 Jun 5.
2
Quantifying clinical relevance in the treatment of schizophrenia.
Clin Ther. 2011 Dec;33(12):B16-39. doi: 10.1016/j.clinthera.2011.11.016.
3
Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?
J Clin Psychiatry. 2011 Dec;72(12):1691-6. doi: 10.4088/JCP.10m06349. Epub 2011 Sep 6.
7
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.
Psychiatry Res. 2011 May 15;187(1-2):42-8. doi: 10.1016/j.psychres.2010.11.017. Epub 2010 Dec 18.
8
Past and present progress in the pharmacologic treatment of schizophrenia.
J Clin Psychiatry. 2010 Sep;71(9):1115-24. doi: 10.4088/JCP.10r06264yel.
9
Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study.
J Clin Psychopharmacol. 2010 Aug;30(4):446-9. doi: 10.1097/JCP.0b013e3181e68e80.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验